05/12/22 8:00 AMNasdaq : LPCN Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study ResultsLipocine Inc.RHEA-AIneutral
05/09/22 8:00 AMNasdaq : LPCN earningsLipocine Announces Financial Results for the First Quarter Ended March 31, 2022Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, today announced financial results for the quarter ended March 31, 2022 and provided a corporateRHEA-AIneutral
04/11/22 8:00 AMNasdaq : LPCN LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTSLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, announced today the appointment of Jill M.RHEA-AIvery positive
03/29/22 7:05 AMNasdaq : LPCN fda approvalLIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, announced today that Antares Pharma, Inc. issued aRHEA-AIvery positive
03/09/22 8:00 AMNasdaq : LPCN earningsLipocine Announces Financial Results for the Year Ended December 31, 2021Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a corporateRHEA-AIneutral
03/01/22 8:00 AMNasdaq : LPCN Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASHLipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today provided an update from the Type C guidance meeting with the U.S. Food and Drug Administration ("FDA") regarding theRHEA-AIvery positive
02/03/22 8:00 AMNasdaq : LPCN LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO®Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products for metabolic and endocrine disorders, today announced that Antares Pharma, Inc. issued a press release announcing that the U.S. Food andRHEA-AIvery positive
01/27/22 8:00 AMNasdaq : LPCN clinical trialLipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the peer-reviewed publication of positive Phase 3 clinical data from the Dosing Validation ("DV") study whichRHEA-AIneutral
01/05/22 8:00 AMNasdaq : LPCN conferencesclinical trialLipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG ConferenceLipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that one abstract has been selected for podium presentation and three abstracts have been selected for posterRHEA-AIneutral
12/22/21 8:00 AMNasdaq : LPCN clinical trialLIPOCINE ANNOUNCES PATIENT DOSED IN ITS PHASE 2 STUDY WITH LPCN 1148 FOR MANAGEMENT OF LIVER CIRRHOSISLipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the first patient has been dosed in its Phase 2 proof-of-concept clinical study (NCT04874350) for the managementRHEA-AIneutral